Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Biotech drugs beneficial but confound cost containment.(Benefits Management)
- Byline: ROBERTO CENICEROS Rapid growth in the price and availability of new specialty drug treatments is posing new challenges for employers' cost management efforts. The drugs, which typically are known as biotechnology-or biotech-drugs, are u Byline: ROBERTO CENICEROS ...
- Research articles 2004-05-03
- Why Biogenerics Will Survive Genzyme's Problems
- The Food and Drug Administration rejected Genzyme's request to sell a version of its drug Myozyme made in a new factory, a decision some journalists and bloggers insist on casting as a black mark against the very notion of generic biotech drugs. There's just one problem: These...
- Blog posts 2008-04-22
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
- A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
- Blog posts 2008-12-31
Additional Resources
- A report by the European Commission stated it would not harmonize a European standard for patenting biotech drug innovations and would allow EU countries to develop their own rules as to what types of human genetic inventions can be protected
- Europe: A report by the European Commission stated it would not harmonize a European standard for patenting biotech drug innovations and would allow EU countries to develop their own rules as to what types of human genetic inventions can be protected. Europe's biotech industry has argued that an EU-wide standard...
- Research articles 2005-07-31
- Opening a path for biotech generics
- A debate has raged for years within the pharmaceutical industry, among generic-drug-makers, and on Capitol Hill about whether to allow lower-cost generic or "follow-on" versions of biotech drugs. With some biologic drugs costing up to $100,000 a year for rare disorders, generics offer the promise of lower costs. The stakes...
- Research articles 2006-09-19
- Cambridge, Mass., Biotech Drug Firm Lands $50 Million in Venture Funding.
- By Beth Healy, The Boston Globe Knight Ridder/Tribune Business News Apr. 6--Archemix Corp., a private drug-development start-up in Cambridge, has landed $50 million in venture capital, providing fresh evidence that investors and venture firms are eager to fund hot biotech companies. ...
- Research articles 2004-04-06
- FDA approves Enbrel drug as a weekly shot.
- By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News Sep. 29--The Food and Drug Administration yesterday approved Amgen's Enbrel as a once-per-week shot, a move that will allow patients to get the biotech drug for inflammatory diseases in a more ...
- Research articles 2004-09-29
- FDA acts to speed up biotech drug approvals. (News).(Brief Article)
- UNDER PRESSURE to streamline the review process for biologics, the Food and Drug Administration FDA announced plans to shift the review of new biotechnology-based drugs from its biologics unit to its drugs unit. Details of the consolidation of so UNDER PRESSURE to streamline the...
- Research articles 2002-09-16
- Rival's Arthritis Drug Beats Seattle-Area Firm for First Time.
- By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News Apr. 23--Immunex's Enbrel started off as the fastest-selling biotech drug ever, but an ongoing shortage has enabled a competing arthritis drug to surpass it in sales. Enbrel sales were $216 million...
- Research articles 2002-04-23
- Receptagen Ltd. proposes spin off of biotech/drug development subsidiaries
- EDMONDS, Washington--BUSINESS WIRE-- May 9, 1996 -- Albert G. Chiasson, Chair and C.E.O. of Receptagen Ltd. (TSE:RCG/OTCBB:RCEPF) announced today that the Board of Directors will present a proposal to alter the corporate structure at its Annual General Meeting.At present, the Company operates two different businesses, each having different capital...
- Research articles 1996-05-09
- Receptagen Ltd. Proposes Spin Off Biotech/Drug Development
- EDMONDS, Wash.--BUSINESS WIRE--May 10, 1996--Albert G. Chaisson, Chair and C.E.O. of Receptagen Ltd. (TSE:RCG/OTCBB:RCEPF) announced today that the Board of Directors will present a proposal to alter the corporate structure at its Annual general Meeting.At present, the company operated two different businesses, each having different capital requirements and, were they...
- Research articles 1996-05-10
- FDA to Biotech: Don't Blame Us For Your Cruddy Data
- For the past few years, a coterie of biotech executives, desperate patients and ideologues have waged a low-level but steady campaign to convince the country that the Food and Drug Administration is condemning sick Americans to death by denying them potentially life-saving cancer drugs and other treatments. For all three,...
- Blog posts 2008-05-29
- Allos Therapeutics: Smallcap Biotech with FDA Catalyst
- Mike Havrilla submits: Allos Therapeutics ALTH is small-cap cancer biotech which filed a NDA on 3/25/09 for pralatrexate (PDX) in the treatment of patients with relapsed/refractory peripheral T-cell lymphoma (PTCL). ALTH requested priority (six-month) review for the application, with an expected 60-day period for the FDA to accept the filing...
- External links 2009-04-27
- Vanda Vaults From Dog House to Drug Approval
- If there was one biotech on every banker's list of cash shells, one dog that could make bankruptcy look like a good option, one name synonymous with snickers and snide comments, it was Vanda Pharmaceuticals. Which makes the FDA's approval of Vanda's schizophrenia drug Fanapt iloperidone surprising, to say the least. ...
- Blog posts 2009-05-08
- Biotech's New Blockbusters -- Oh, Really?
- Biotech's New Blockbusters -- Oh, Really?20 to 30 Blockbusters of Biotech Exist NowInnovation in Pharmacology?Beginning in the 1970, biopharmaceuticals were being researched for conceptual production in those places once called academic institutions. The first biopharmaceutical ever was a synthetic insulin called Humulin made by Genetech in 1982. Later...
- Discussion threads 2008-07-10
- Novel anticancer drug on track.(Life Sciences)(GPC Biotech AG)(Brief Article)
- THE FOOD and Drug Administration FDA has granted fast track status to a new anticancer drug, satraplatin, being developed by GPC Biotech AG as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer HRPC. The c THE FOOD and Drug Administration FDA has...
- Research articles 2003-09-29
- Man Bites Dog: Former Merck CEO Blasts High Drug Prices
- Most pharmaceutical companies insist that high drug prices are a natural consequence of the risky business of drug discovery, and that huge profits on marketed drugs are necessary to cover the costs of the 5,000 to 10,000 experimental drugs that fail for every one that succeeds. In fact, there are...
- Blog posts 2008-05-05
- British Biotech and MethylGene sign agreement on phase II antisense drug.(MG98, MethylGene's anti- cancer drug)
- Biotech plc (Oxford, England; 44 (0) 20 7269 7285) and MethylGene, Inc. (Montreal, Canada; 514-337-3333), a privately-held Canadian biopharmaceuticals company, announced that they have entered into a collaboration granting British Biotech the European development and commercialization rights for MG98, MethylGene's leading experimental anti- cancer drug,...
- Research articles 2002-02-01
- Nautilus Biotech Announces IND Filing for its Injectable Long-Lasting INTERFERON-alpha, BELEROFON(R).
- PARIS, October 10 /PRNewswire/ -- Nautilus Biotech has announced that it has submitted an Investigational New Drug IND filing to the U.S. Food and Drug Administration FDA for injectable BELEROFONR, its protease-resistant, long-lasting Inter PARIS, October 10 /PRNewswire/ -- ...
- Research articles 2006-10-10
- Building Biotech in Ohio - You can if You Think You can
- Biotechnology sometimes raises profound questions about the nature of life and humanity. A local reporter will call a local company or biotech association for comment on these issues, so biotech CEOs and high-ranking officials have to be prepared. What does all this mean? The industry's public profile and public expectations...
- White papers 2002-12-02
- << Previous
- page 1 of 1
- Next >>
